National Institutes of Health Clinical Center (CC) psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
National Institutes of Health Clinical Center (CC) is listed with 8 registered studies counted here, in Bethesda, United States. By compound: 8 ketamine. By registry status: 4 recruiting, 2 completed and 2 terminated. By phase: 1 early phase 1, 5 phase 1 and 2 phase 2. Reported start years run from 2004 (earliest) to 2024 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 8 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Ketamine | 8 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 4 | 50% |
| Completed | 2 | 25% |
| Terminated | 2 | 25% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 13% |
| Phase 1 | 5 | 63% |
| Phase 2 | 2 | 25% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression | NCT06511908 | Recruiting | Phase 2 | 2024-11-06 | Ketamine |
| [11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine | NCT05522673 | Terminated | Phase 1 | 2023-02-08 | Ketamine |
| A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue | NCT04141696 | Completed | Phase 1 | 2021-07-26 | Ketamine |
| Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression | NCT03973268 | Recruiting | Phase 1 | 2020-01-21 | Ketamine |
| Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder | NCT03065335 | Recruiting | Phase 1 | 2017-05-25 | Ketamine |
| Neurobiology of Suicide | NCT02543983 | Recruiting | Phase 2 | 2015-12-01 | Ketamine |
| Effect of Ketamine on Fatigue Following Cancer Therapy | NCT02317341 | Terminated | Early Phase 1 | 2014-12-13 | Ketamine |
| Rapid Antidepressant Effects of Ketamine in Major Depression | NCT00088699 | Completed | Phase 1 | 2004-07-26 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.